BACKGROUND: Adult survivors of childhood acute lymphoblastic leukemia (ALL) are at increased cardiovascular risk. Studies of factors including treatment exposures that may modify risk of low cardiorespiratory fitness in this population have been limited. PROCEDURE: To assess cardiorespiratory fitness, maximal oxygen uptake (VO2 max) was measured in 115 ALL survivors (median age, 23.5 years; range 18-37). We compared VO2 max measurements for ALL survivors to those estimated from submaximal testing in a frequency-matched (age, gender, race/ethnicity) 2003-2004 National Health and Nutritional Examination Survey (NHANES) cohort. Multivariable linear regression models were constructed to evaluate the association between therapeutic exposures and outcomes of interest. RESULTS: Compared to NHANES participants, ALL survivors had a substantially lower VO2 max (mean 30.7 vs. 39.9 ml/kg/min; adjusted P < 0.0001). For any given percent total body fat, ALL survivors had an 8.9 ml/kg/min lower VO2 max than NHANES participants. For key treatment exposure groups (cranial radiotherapy [CRT], anthracycline chemotherapy, or neither), ALL survivors had substantially lower VO2 max compared with NHANES participants (all comparisons, P < 0.001). Almost two-thirds (66.7%) of ALL survivors were classified as low cardiorespiratory fitness compared with 26.3% of NHANES participants (adjusted P < 0.0001). In multivariable models including only ALL survivors, treatment exposures were modestly associated with VO2 max. Among females, CRT was associated with low VO2 max (P = 0.02), but anthracycline exposure was not (P = 0.58). In contrast, among males, anthracycline exposure ≥ 100 mg/m(2) was associated with low VO2 max (P = 0.03), but CRT was not (P = 0.54). CONCLUSION: Adult survivors of childhood ALL have substantially lower levels of cardiorespiratory fitness compared with a similarly aged non-cancer population.
BACKGROUND: Adult survivors of childhood acute lymphoblastic leukemia (ALL) are at increased cardiovascular risk. Studies of factors including treatment exposures that may modify risk of low cardiorespiratory fitness in this population have been limited. PROCEDURE: To assess cardiorespiratory fitness, maximal oxygen uptake (VO2 max) was measured in 115 ALL survivors (median age, 23.5 years; range 18-37). We compared VO2 max measurements for ALL survivors to those estimated from submaximal testing in a frequency-matched (age, gender, race/ethnicity) 2003-2004 National Health and Nutritional Examination Survey (NHANES) cohort. Multivariable linear regression models were constructed to evaluate the association between therapeutic exposures and outcomes of interest. RESULTS: Compared to NHANESparticipants, ALL survivors had a substantially lower VO2 max (mean 30.7 vs. 39.9 ml/kg/min; adjusted P < 0.0001). For any given percent total body fat, ALL survivors had an 8.9 ml/kg/min lower VO2 max than NHANESparticipants. For key treatment exposure groups (cranial radiotherapy [CRT], anthracycline chemotherapy, or neither), ALL survivors had substantially lower VO2 max compared with NHANESparticipants (all comparisons, P < 0.001). Almost two-thirds (66.7%) of ALL survivors were classified as low cardiorespiratory fitness compared with 26.3% of NHANESparticipants (adjusted P < 0.0001). In multivariable models including only ALL survivors, treatment exposures were modestly associated with VO2 max. Among females, CRT was associated with low VO2 max (P = 0.02), but anthracycline exposure was not (P = 0.58). In contrast, among males, anthracycline exposure ≥ 100 mg/m(2) was associated with low VO2 max (P = 0.03), but CRT was not (P = 0.54). CONCLUSION: Adult survivors of childhood ALL have substantially lower levels of cardiorespiratory fitness compared with a similarly aged non-cancer population.
Authors: Jyoti Malhotra; Emily S Tonorezos; Marina Rozenberg; Gloria L Vega; Charles A Sklar; Joanne Chou; Chaya S Moskowitz; Debra A Eshelman-Kent; Peter Janiszewski; Robert Ross; Kevin C Oeffinger Journal: J Lipid Res Date: 2012-09-13 Impact factor: 5.922
Authors: Kevin C Oeffinger; Ann C Mertens; Charles A Sklar; Yutaka Yasui; Thomas Fears; Marilyn Stovall; Terry A Vik; Peter D Inskip; Leslie L Robison Journal: J Clin Oncol Date: 2003-04-01 Impact factor: 50.717
Authors: Julie A Ross; Kevin C Oeffinger; Stella M Davies; Ann C Mertens; Erica K Langer; William R Kiffmeyer; Charles A Sklar; Marilyn Stovall; Yutaka Yasui; Leslie L Robison Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 50.717
Authors: Emily S Tonorezos; Melissa M Hudson; Angela B Edgar; Leontien C Kremer; Charles A Sklar; W Hamish B Wallace; Kevin C Oeffinger Journal: Lancet Diabetes Endocrinol Date: 2015-04-12 Impact factor: 32.069
Authors: Kirsten K Ness; Gregory T Armstrong; Mondira Kundu; Carmen L Wilson; Tamara Tchkonia; James L Kirkland Journal: Cancer Date: 2014-12-19 Impact factor: 6.860
Authors: Vesile Yildiz Kabak; Patrick Calders; Tulin Duger; Jibril Mohammed; Eric van Breda Journal: Support Care Cancer Date: 2018-09-25 Impact factor: 3.603
Authors: David Mizrahi; Joanna E Fardell; Richard J Cohn; Robyn E Partin; Carrie R Howell; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Jamie McBride; Penelope Field; Claire E Wakefield; David Simar Journal: Int J Cancer Date: 2019-12-17 Impact factor: 7.396
Authors: Carmen L Wilson; Carrie R Howell; Robyn E Partin; Lu Lu; Sue C Kaste; Daniel A Mulrooney; Ching-Hon Pui; Jennifer Q Lanctot; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kirsten K Ness Journal: Pediatr Blood Cancer Date: 2018-07-29 Impact factor: 3.167
Authors: Megan E Slater; Julia Steinberger; Julie A Ross; Aaron S Kelly; Eric J Chow; Ildiko H Koves; Paul Hoffmeister; Alan R Sinaiko; Anna Petryk; Antoinette Moran; Jill Lee; Lisa S Chow; K Scott Baker Journal: Biol Blood Marrow Transplant Date: 2015-04-10 Impact factor: 5.742
Authors: Kirsten K Ness; Sue C Kaste; Liang Zhu; Ching-Hon Pui; Sima Jeha; Paul C Nathan; Hiroto Inaba; Karen Wasilewski-Masker; Durga Shah; Robert J Wells; Robyn E Karlage; Leslie L Robison; Cheryl L Cox Journal: Leuk Lymphoma Date: 2014-08-20
Authors: Kirsten K Ness; Juan C Plana; Vijaya M Joshi; Russell V Luepker; Jean B Durand; Daniel M Green; Robyn E Partin; Aimee K Santucci; Rebecca M Howell; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong Journal: J Clin Oncol Date: 2019-10-17 Impact factor: 50.717